Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Phospho-TrkA (Tyr791) Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA537671
Description
A suggested positive control for IHC is human brain tissue.
NTRK1 (TRKA) belongs to the neurotrophic factor family of related polypeptides central to the development and maintenance of the mammalian nervous system. TrkA is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. The presence of TrkA leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TrkA have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer.
Specifications
| Phospho-TrkA (Tyr791) | |
| Polyclonal | |
| Unconjugated | |
| Ntrk1 | |
| C80751; DKFZp781I14186; EC 2.7.10.1; gp140trk; high affinity nerve growth factor receptor; kinase TrkA; MTC; neurotrophic receptor tyrosine kinase 1; Neurotrophic tyrosine kinase receptor type 1; neurotrophic tyrosine kinase, receptor, type 1; Ntrk1; Oncogene TRK; p140-TrkA; Slow nerve growth factor receptor; Tkr; TRK; TRK1; TRK1-transforming tyrosine kinase protein; Trka; Trk-A; TrkA neurotrophin receptor; trkA proto-oncogene receptor; tropomyosin-related kinase A; Tyrosine kinase receptor; Tyrosine kinase receptor A | |
| Rabbit | |
| Affinity Chromatography | |
| RUO | |
| 4914 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (Paraffin) | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| P04629 | |
| Ntrk1 | |
| Peptide sequence around phosphorylation site of tyrosine 791 (P-V-Y(p)-L-D) derived from Human Trk A. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction